
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health has demonstrated strong growth potential, evidenced by a remarkable 70% year-over-year increase in subscribers in the fourth quarter and an expanding international portfolio that contributes to incremental revenue. The company is strategically positioned to capitalize on emerging weight-loss opportunities, particularly through partnerships that may enhance revenue contributions from new weight-loss drugs like CagriSema and Amycretin, which are currently in trials. Additionally, the diversification of its offerings beyond just weight loss, including ongoing growth in specialties like sexual health, mitigates concentration risk and supports the company's overall financial resilience and growth trajectory.
Bears say
Hims & Hers Health is experiencing a significant slowdown in revenue growth, as evidenced by disappointing fourth quarter 2025 earnings results and weak guidance for the first quarter of 2026. Full-year 2026 revenue expectations have been downgraded to between $2.7 billion and $2.9 billion, significantly lower than prior estimates and reflecting a decline in projected revenue and EBITDA figures for fiscal year 2027. Additionally, the company faces increasing legal and regulatory risks, further compounding concerns about its future financial performance.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares